<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <source-app name="Horizon">Horizon</source-app>
      <rec-number>1</rec-number>
      <foreign-keys>
        <key app="Horizon" db-id="fdi:010059621">1</key>
      </foreign-keys>
      <ref-type name="Journal Article">17</ref-type>
      <work-type>ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES</work-type>
      <contributors>
        <authors>
          <author>
            <style face="bold" font="default" size="100%">Lienhardt, Christian</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Raviglione, M.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Spigelman, M.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Hafner, R.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Jaramillo, E.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Hoelscher, M.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Zumla, A.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Gheuens, J.</style>
          </author>
        </authors>
      </contributors>
      <titles>
        <title>New drugs for the treatment of tuberculosis : needs, challenges, promise, and prospects for the future</title>
        <secondary-title>Journal of Infectious Diseases</secondary-title>
      </titles>
      <pages>S241-S249</pages>
      <keywords>
        <keyword>INFECTION</keyword>
        <keyword>TRAITEMENT MEDICAL</keyword>
        <keyword>MEDICAMENT</keyword>
        <keyword>SENSIBILITE RESISTANCE</keyword>
        <keyword>SIDA</keyword>
        <keyword>ENFANT</keyword>
        <keyword>TOLERANCE</keyword>
        <keyword>EFFICACITE</keyword>
        <keyword>REGLEMENTATION</keyword>
        <keyword>TUBERCULOSE</keyword>
        <keyword>COMBINAISON MEDICAMENTEUSE</keyword>
        <keyword>COINFECTION</keyword>
        <keyword>INTERACTION MEDICAMENTEUSE</keyword>
        <keyword>SECURITE SANITAIRE</keyword>
        <keyword>RECOMMANDATION</keyword>
        <keyword>ANTIRETROVIRAUX</keyword>
        <keyword>ACCES AUX SOINS</keyword>
        <keyword>FLUOROQUINOLONE</keyword>
        <keyword>GATIFLOXACINE</keyword>
        <keyword>MOXIFLOXACINE</keyword>
        <keyword>RIFAPENTINE</keyword>
        <keyword>ISONIAZIDE</keyword>
        <keyword>BEDAQUILINE</keyword>
        <keyword>DELAMANIDE</keyword>
        <keyword>NITROIMIDAZOLE</keyword>
        <keyword>PYRAZINAMIDE</keyword>
      </keywords>
      <dates>
        <year>2012</year>
      </dates>
      <call-num>fdi:010059621</call-num>
      <language>ENG</language>
      <periodical>
        <full-title>Journal of Infectious Diseases</full-title>
      </periodical>
      <isbn>0022-1899</isbn>
      <number>suppl. 2</number>
      <electronic-resource-num>10.1093/infdis/jis034</electronic-resource-num>
      <urls>
        <related-urls>
          <url>https://www.documentation.ird.fr/hor/fdi:010059621</url>
        </related-urls>
        <pdf-urls>
          <url>https://www.documentation.ird.fr/intranet/publi/depot/2013-07-12/010059621.pdf</url>
        </pdf-urls>
      </urls>
      <volume>205</volume>
      <remote-database-provider>Horizon (IRD)</remote-database-provider>
      <custom6>050MEDECI</custom6>
    </record>
  </records>
</xml>
